Goodwin Advises Qureight on a $20 Million Series B Financing Investment
The Technology team advised Qureight on its $20 million Series B financing investment, led by Molten Ventures. Existing investors Hargreave Hale AIM VCT, XTX Ventures, Guinness Ventures, Meltwind, and Ascension also participated in the round. The new capital will support expansion of the company’s 3D deep learning imaging portfolio, alongside commercial expansion to address demand across key new therapeutic markets for lung and heart diseases.
Qureight is an end-to-end imaging company that provides enterprise-grade imaging and precision endpoints for clinical trials with a focus on lung and heart disease. They provide automated image management and AI analysis in therapeutic areas such as idiopathic pulmonary fibrosis, progressive pulmonary fibrosis, pulmonary hypertension, and bronchiectasis.
The Goodwin team was led by Andrew Davis, Lucy Thomas, Gaspard du Chaffaut, and Hakyung Lee.
For more information on the deal, please read the press release.